The ASAM Review Course in Addiction Medicine 2019 (20.5 CME)

4.85 (26 votes)

image

Overview

The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

The course offers recorded sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

Learning Objectives

Upon completion, participants should be able to:

  1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
  2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
  3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
  4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
  5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

Additional Resources

Additional Board Exam Preparation resources and tools are also available.


 

  • Evaluation and Certificate - ASAM Review Course 2019

    Contains 2 Component(s), Includes Credits

    CME Evaluation for the ASAM Review Course 2019

    Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Board Exam Practice Questions & Expert Panel Discussion (4.25 CME)

    Contains 8 Component(s), Includes Credits

    Earn 4.25 AMA PRA Category 1 Credits while watching an expert panel reviews questions from the attendees of The ASAM Review Course in Addiction Medicine 2018.

    (4.25 CME) In this session recording from The ASAM Review Course in Addiction Medicine 2019, an expert panel reviews questions from the attendees of The ASAM Review Course in Addiction Medicine 2019

  • Session 2: Alcohol (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about screening for alcohol use disorder, alcohol withdrawal management and Relapse Prevention Medications in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about  the basic concepts of alcohol use disorder: Standard drink sizes, screening for alcohol use disorder, an introduction to alcohol withdrawal management and the use of Relapse Prevention Medications

    Ricardo Restrepo

    MD, MPH

    Ricardo Restrepo Guzman MD, MPH finished his medical school in Medellin, Colombia. He completed his residency training in Psychiatry at Boston University Medical Center and a fellowship in Addiction Psychiatry at the same institution. He received a Master's degree in Global Public Health from New York University in 2008, while working at St Luke's Roosevelt Hospital Center, an academic institution affiliated with Columbia University, where he was the Director of the Addiction Psychopharmacology Clinic at the Addiction Institute of New York, as well as Attending Psychiatrist at the Adult Outpatient Clinic. 

    He remains affiliated with the Addiction Institute of New York as a faculty member. In 2012 he started to work at the Long Beach VA Hospital, where he is the Medical Director of the Substance Abuse Treatment Program/Buprenorphine Clinic as well as an Attending Psychiatrist at the Department of Mental Health. Ricardo holds an academic position as Assistant Clinical Professor of Psychiatry and Human Behavior at the University of California Irvine School of Medicine. He teaches and supervises students, psychiatry, family medicine residents and staff at the Long Beach VA Hospital and works with the diverse population of Los Angeles and Orange Counties. 

    His academic interests include the psychotherapy and psychopharmacology of addiction,the teaching of Psychiatry and Addiction Medicine around the United States and other countries. He is actively involved in issues related to transcultural psychiatry, human rights, and behavioral addictions. Ricardo has worked with immigrant populations in the United States for over 15 years. He is also a volunteer physician for Physicians for Human Rights (PHR}. He has conducted medical evaluations and clinical treatment of people who have survived torture and other forms of abuse,and has served as a United Nations Consultant since 2005. 

    Ricardo writes monthly for the Colombian healthcare newspaper EJ Pulso, among other publications in the medical field. He has written chapters for addiction and human rights textbooks. He Is the co-author of textbooks on buprenorphine as well as women's health and addiction. Most recently Ricardo cooperate with the APA/ DSM-5 Translation to Spanish language. He is board certified in Psychiatry and Addiction Psychiatry.

  • Session 3: Sedatives (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about withdrawal from sedatives, benzodiazepines, barbiturates and GHB in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the basic concepts of sedative use disorder: Neurobiology, an introduction to sedative withdrawal and the use of clinical strategies to address intoxication and withdrawal of benzodiazepines, barbiturates and GHB.

    Ricardo Restrepo

    MD, MPH

    Ricardo Restrepo Guzman MD, MPH finished his medical school in Medellin, Colombia. He completed his residency training in Psychiatry at Boston University Medical Center and a fellowship in Addiction Psychiatry at the same institution. He received a Master's degree in Global Public Health from New York University in 2008, while working at St Luke's Roosevelt Hospital Center, an academic institution affiliated with Columbia University, where he was the Director of the Addiction Psychopharmacology Clinic at the Addiction Institute of New York, as well as Attending Psychiatrist at the Adult Outpatient Clinic. 

    He remains affiliated with the Addiction Institute of New York as a faculty member. In 2012 he started to work at the Long Beach VA Hospital, where he is the Medical Director of the Substance Abuse Treatment Program/Buprenorphine Clinic as well as an Attending Psychiatrist at the Department of Mental Health. Ricardo holds an academic position as Assistant Clinical Professor of Psychiatry and Human Behavior at the University of California Irvine School of Medicine. He teaches and supervises students, psychiatry, family medicine residents and staff at the Long Beach VA Hospital and works with the diverse population of Los Angeles and Orange Counties. 

    His academic interests include the psychotherapy and psychopharmacology of addiction,the teaching of Psychiatry and Addiction Medicine around the United States and other countries. He is actively involved in issues related to transcultural psychiatry, human rights, and behavioral addictions. Ricardo has worked with immigrant populations in the United States for over 15 years. He is also a volunteer physician for Physicians for Human Rights (PHR}. He has conducted medical evaluations and clinical treatment of people who have survived torture and other forms of abuse,and has served as a United Nations Consultant since 2005. 

    Ricardo writes monthly for the Colombian healthcare newspaper EJ Pulso, among other publications in the medical field. He has written chapters for addiction and human rights textbooks. He Is the co-author of textbooks on buprenorphine as well as women's health and addiction. Most recently Ricardo cooperate with the APA/ DSM-5 Translation to Spanish language. He is board certified in Psychiatry and Addiction Psychiatry.

  • Session 4: Opioids (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about botany and composition of opioids, opioid receptors and endogenous ligands in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about botany and the composition of opium and it's alkaloids.The basic science of the opioid receptors and their endogenous ligands will be reviewed. Physiologic effects and adverse effects, including withdrawal and overdose syndromes will be described. Comprehensive treatment of opioid use disorder will be explained.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

  • Session 5: Tobacco (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about nicotine use disorder and various treatment options in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the epidemiology and health consequences of tobacco use. It will review the pharmacology of nicotine and the clinical manifestations of nicotine use disorder and compare various treatment options. It will also discuss the current evidence regarding electronic cigarettes.

    Annie Levesque

    MD, MSc

    Dr. Annie Levesque is the Medical Director of the Opioid Treatment Program at the Addiction Institute at Mount Sinai West. She is also the Associate Director of the Fellowship in Addiction Medicine Program at the Icahn School of Medicine at Mount Sinai. After receiving her medical degree from the University of Montreal, Dr. Levesque completed a Family Medicine and a Clinician-Scholar residency program at the University of Montreal, an Addiction Medicine fellowship at Mount Sinai West Hospital and a Masters in Experimental Medicine at McGill University.

  • Session 6: Cannabis (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about diagnosis and treatment considerations for cannabis in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the epidemiology, background on the substance, pharmacokinetics and pharmacodynamics, diagnosis, and treatment considerations for cannabis and substances that act on the cannabinoid system.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego. Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions. She previously worked at a large outpatient addiction treatment program serving over 5000 patients. Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders. She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction. During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships. She completed a fellowship in Addiction Psychiatry at Yale. During residency and her early faculty years, she founded and led the Yale Global Mental Health Program. She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry. She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program and a new Addiction Psychiatry Fellowship.

  • Session 7: Stimulants (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about pharamlogical effects and molecular mechanisms of action for absued stimulant drugs in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about methods of use, pharmacological effects, and molecular mechanisms of action for abused stimulant drugs, including cocaine, methamphetamine and newer "bath salts" cathinones.  Clinical approaches for treating adverse effects and stimulant use disorders will be discussed.

    Michael Baumann

    PhD

    Michael H. Baumann, Ph.D. is a Staff Scientist and Chief of the Designer Drug Research Unit (DDRU), at the Intramural Research Program (IRP) of the National Institute on Drug Abuse (NIDA) in Baltimore, Maryland.  The DDRU collects, analyzes and disseminates the most up-to-date information about the pharmacology and toxicology of newly-emerging synthetic drugs of abuse (i.e., designer drugs), more formally known as new psychoactive substances (NPS).  Working with partner organizations such as the Drug Enforcement Administration (DEA) and the National Drug Early Warning System (NDEWS), Dr. Baumann is kept informed about trends in the misuse of NPS.  The DDRU has characterized the molecular mechanism of action and pharmacological effects for a diversity of NPS, including “bath salts” (synthetic stimulants), “spice” (synthetic cannabinoids) and synthetic opioids.  Findings from the DDRU inform law enforcement personnel, health care workers, clinical toxicologists, forensic scientists, basic researchers, and policymakers who are involved in responding to the global spread of NPS and the associated public health risks. 

  • Session 8: Other Classes of Drugs (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about hallucinogens, dissociatives, inhalants and steroids in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about a diverse group of substances including hallucinogens, dissociatives, inhalants and steroids.  The physiological effects and epidemiology will be presented, along with notable examples of each class.  Features of specific substance use disorders as well as treatment options will also be discussed.

    Abigail J. Herron

    DO, DFASAM, FAPA

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  

    Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  

    Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

  • Session 9: Behavioral Addictions (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about gambling disorder, internet gaming disorder and other non-DSM behavioral addictions in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about behavioral addictions with a focus on gambling disorder and internet gaming disorder. Other non-DSM behavioral addictions will also be discussed.

    Erin A. Zerbo

    MD, FASAM

    Erin Zerbo, MD, FASAM is an Assistant Professor in the Department of Psychiatry at Rutgers New Jersey Medical School, and the Associate Director of Medical Student Education. She will serve as Director of the Wellness Center at University Hospital when it opens in Fall 2015.

    She received her B.S. in Brain and Cognitive Sciences from the Massachusetts Institute of Technology in 2003, and her M.D. from New York University School of Medicine in 2007. She continued in a psychiatry residency at New York University, where she served as chief resident during her PGY-IV year and received the Harold I. Kaplan Memorial Award for excellence in teaching and the Wendy Rives Memorial Award for compassion in working with the severely mentally ill. Following residency, she remained at NYU for a one-year fellowship in Addiction Psychiatry.

    Prior to her faculty position at Rutgers, Dr. Zerbo served as the Associate Director of the Consultation-Liaison Psychiatry Service at Bellevue Hospital and the Associate Director of the NYU Addiction Psychiatry fellowship.

    Dr. Zerbo's primary interest has always been the treatment of addiction in the context of public psychiatry. She is especially interested in the pharmacotherapy of substance use disorders among underserved populations, and in addressing systemic barriers to integrated and continuous care. Recent publications include a chapter entitled “Co-occurring Personality Disorders and Addiction" in The ASAM Principles of Addiction Medicine textbook, and an article accepted for publication in the Harvard Review of Psychiatry which explores how to improve attitudes of psychiatry residents toward patients with substance use disorders.

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ASAM CME Committee and Reviewers Disclosure Listing

First Name Commercial Interests Compensation Received For what Role?
Timothy Brennan MD, MPH, FASAM None
Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
James Finch MD, DFASAM None

Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
Adam Gordon, MD, MPH None
Leslie Hayes, MD None
Abigail Herron DO, DFASAM None
Petros Levounis MD, MA, FASAM None
Carla Marienfeld MD None
Ricardo Restrepo MD, MPH, FASAM None
Richard Ries MD, DFASAM None
Edwin Salsitz MD, DFASAM None
Sharon Stancliff MD, FASAM None
Timothy Wiegand MD, FACMT, FAACT None
Erin Zerbo, MD None
ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

Upon completion, participants should be able to:

  1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
  2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
  3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
  4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
  5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.

The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

  • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
  • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
  • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients